4//SEC Filing
Allan Jonathan 4
Accession 0001966716-25-000006
CIK 0001623526other
Filed
Dec 2, 7:00 PM ET
Accepted
Dec 3, 8:20 PM ET
Size
14.7 KB
Accession
0001966716-25-000006
Insider Transaction Report
Form 4
Allan Jonathan
GENERAL COUNSEL & CORP SEC
Transactions
- Exercise/Conversion
Common Stock
2025-12-01+12,357→ 24,188 total - Sale
Common Stock
2025-12-02$29.56/sh−1,416$41,860→ 22,772 total - Sale
Common Stock
2025-12-02$30.14/sh−868$26,163→ 21,904 total - Sale
Common Stock
2025-12-03$30.34/sh−898$27,244→ 21,006 total - Sale
Common Stock
2025-12-03$30.85/sh−1,394$43,002→ 19,612 total - Exercise/Conversion
Restricted Stock Units
2025-12-01−12,357→ 0 totalExp: 2025-12-01→ Common Stock (12,357 underlying)
Footnotes (7)
- [F1]The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.
- [F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.93 to $29.92 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 through 5.
- [F3]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.93 to $30.63 per share, inclusive.
- [F4]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.81 to $30.805 per share, inclusive.
- [F5]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.815 to $31.17 per share, inclusive.
- [F6]Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
- [F7]33,927 restricted stock units from this award vested on December 1, 2024 and 12,357 vest on December 1, 2025, subject to the reporting person's continued service to the Issuer on each such date.
Documents
Issuer
Stoke Therapeutics, Inc.
CIK 0001623526
Entity typeother
Related Parties
1- filerCIK 0001966716
Filing Metadata
- Form type
- 4
- Filed
- Dec 2, 7:00 PM ET
- Accepted
- Dec 3, 8:20 PM ET
- Size
- 14.7 KB